Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Circulating Biomarker for Liquid Biopsy Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Circulating Biomarker for Liquid Biopsy Market Status and Forecast (2016-2027)
      • 1.3.2 Global Circulating Biomarker for Liquid Biopsy Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Circulating Biomarker for Liquid Biopsy Supply by Company

    • 2.1 Global Circulating Biomarker for Liquid Biopsy Sales Value by Company
    • 2.2 Circulating Biomarker for Liquid Biopsy Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Circulating Biomarker for Liquid Biopsy Market Status by Category

    • 3.1 Circulating Biomarker for Liquid Biopsy Category Introduction
      • 3.1.1 Circulating Tumor Cells (CTCs)
      • 3.1.2 Circulating Tumor DNA (ctDNA)
      • 3.1.3 Cell-Free DNA (cfDNA)
      • 3.1.4 Extracellular Vesicles (EVs)
      • 3.1.5 Others
    • 3.2 Global Circulating Biomarker for Liquid Biopsy Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Circulating Biomarker for Liquid Biopsy Market Status by End User/Segment

    • 4.1 Circulating Biomarker for Liquid Biopsy Segment by End User/Segment
      • 4.1.1 Early Cancer Screening
      • 4.1.2 Therapy Selection
      • 4.1.3 Treatment Monitoring
      • 4.1.4 Recurrence Monitoring Orthopedics
    • 4.2 Global Circulating Biomarker for Liquid Biopsy Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Circulating Biomarker for Liquid Biopsy Market Status by Region

    • 5.1 Global Circulating Biomarker for Liquid Biopsy Market by Region
    • 5.2 North America Circulating Biomarker for Liquid Biopsy Market Status
    • 5.3 Europe Circulating Biomarker for Liquid Biopsy Market Status
    • 5.4 Asia Pacific Circulating Biomarker for Liquid Biopsy Market Status
    • 5.5 Central & South America Circulating Biomarker for Liquid Biopsy Market Status
    • 5.6 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Status

    6 North America Circulating Biomarker for Liquid Biopsy Market Status

    • 6.1 North America Circulating Biomarker for Liquid Biopsy Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Circulating Biomarker for Liquid Biopsy Market Status

    • 7.1 Europe Circulating Biomarker for Liquid Biopsy Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Circulating Biomarker for Liquid Biopsy Market Status

    • 8.1 Asia Pacific Circulating Biomarker for Liquid Biopsy Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Circulating Biomarker for Liquid Biopsy Market Status

    • 9.1 Central & South America Circulating Biomarker for Liquid Biopsy Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Status

    • 10.1 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Circulating Biomarker for Liquid Biopsy Market Forecast by Category and by End User/Segment

    • 12.1 Global Circulating Biomarker for Liquid Biopsy Sales Value Forecast (2022-2027)
    • 12.2 Global Circulating Biomarker for Liquid Biopsy Forecast by Category
    • 12.3 Global Circulating Biomarker for Liquid Biopsy Forecast by End User/Segment

    13 Global Circulating Biomarker for Liquid Biopsy Market Forecast by Region/Country

    • 13.1 Global Circulating Biomarker for Liquid Biopsy Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 GE Healthcare
      • 14.1.1 Company Information
      • 14.1.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.1.3 GE Healthcare Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Fluxion Biosciences
      • 14.2.1 Company Information
      • 14.2.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.2.3 Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Epigenomics AG
      • 14.3.1 Company Information
      • 14.3.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.3.3 Epigenomics AG Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Biocept
      • 14.4.1 Company Information
      • 14.4.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.4.3 Biocept Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Becton, Dickinson and Company
      • 14.5.1 Company Information
      • 14.5.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.5.3 Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Agilent Technologies
      • 14.6.1 Company Information
      • 14.6.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.6.3 Agilent Technologies Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Affymetrix
      • 14.7.1 Company Information
      • 14.7.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.7.3 Affymetrix Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Abbott Laboratories
      • 14.8.1 Company Information
      • 14.8.2 Circulating Biomarker for Liquid Biopsy Product Introduction
      • 14.8.3 Abbott Laboratories Circulating Biomarker for Liquid Biopsy Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Circulating Biomarker for Liquid Biopsy market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Circulating Biomarker for Liquid Biopsy market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Circulating Tumor Cells (CTCs)
      Circulating Tumor DNA (ctDNA)
      Cell-Free DNA (cfDNA)
      Extracellular Vesicles (EVs)
      Others

      Segmented by End User/Segment
      Early Cancer Screening
      Therapy Selection
      Treatment Monitoring
      Recurrence Monitoring Orthopedics

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      GE Healthcare
      Fluxion Biosciences
      Epigenomics AG
      Biocept
      Becton, Dickinson and Company
      Agilent Technologies
      Affymetrix
      Abbott Laboratories
      Buy now